Fixed-Dose Combination Antidiabetic Therapy: Real-World Factors Associated with Prescribing Choices and Relationship with Patient Satisfaction and Compliance

Benford, M; Milligan, Gary; Pike, James; Anderson, Peter; Piercy, James; Fermer, Steve

doi:10.1007/s12325-011-0096-z

Cited by 53 publications

(45 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies confirm that utilization of FDC improves compliance of the patients and decreases the cost of therapy for the cardiovascular diseases and their consequences in case of bad control [32, 33,34].…”

Section: Fig 4 Changes In Reference Price Per Ddd For the Fdcs Of Amentioning

confidence: 99%

Fixed Doses Combinations Acting on Cardiovascular System - Utilization and Generic Competition

Mitkova

Manova²,

Georgieva

et al. 2016

AIR

View full text Add to dashboard Cite

2 -inhibitors and diuretics, angiotensin receptor blockers (AT receptor blockers, ARBs, sartans) and diuretics. Many new generic molecules as FDCs enter the PDL, thus leading to decrease in the reference price, because of generic competition. The decrease is significant in the new therapeutic groups. The changes in utilization calculated as defined daily dose (DDD)/1000 inhabitants/day show higher utilization in 2013 for the groups of ACE inhibitors and diuretics and AT receptor blockers and diuretics (Enalapril/ Hydrochlorthiazide (HCTZ), Perindopril/ Indapamide, Valsartan/HCTZ, Losartan/ HCTZ). Conclusion:The study confirms that in Bulgaria the generic and therapeutic competition has increased during 2009-2013. It leads to significant price decrease and changes in the trends in utilization of the FDC in cardiology.

show abstract

Section: Fig 4 Changes In Reference Price Per Ddd For the Fdcs Of Amentioning

confidence: 99%

Fixed Doses Combinations Acting on Cardiovascular System - Utilization and Generic Competition

Mitkova

Manova²,

Georgieva

et al. 2016

AIR

View full text Add to dashboard Cite

show abstract

“…Products that are single-pill FDCs offer several advantages over multiple-pill combinations [12,35]. They reduce the complexity of a dosing regimen, which is associated with improved patient adherence with treatment [35][36][37]. The lower doses of the two agents in an FDC product may offer greater efficacy in combination than that provided by higher or maximal doses of monotherapy [38][39][40], or of coadministered dual therapy [37].…”

Section: Approaches To Combination Therapy: Advantages and Disadvantagesmentioning

confidence: 99%

Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals

Lavernia¹,

Adkins²,

Shubrook

2015

Postgraduate Medicine

View full text Add to dashboard Cite

The management of type 2 diabetes mellitus (T2DM) by primary care physicians (PCPs) has become increasingly complex due to limitations on consultation time, an increasing array of drug treatment options, and issues of comorbidities and polypharmacy. Diabetes is a progressive condition and treatment with a single glucose-lowering agent can only address limited pathophysiologic targets and does not provide adequate glycemic control in many cases. Consequently, most patients with T2DM will eventually require treatment with multiple glucoselowering medications. Oral combination therapy in T2DM may be given as multiple-pills, or as single-pill, fixed-dose combinations (FDCs), the latter of which offer convenience, ease of administration, and a reduction in the medication burden. Therefore, FDCs can potentially improve patients' treatment adherence and optimize achievement and maintenance of glycemic targets. However, cost factors also need to be considered. An understanding of the issues associated with the use of combination therapy in T2DM will help PCPs to guide patient-centered decision making and promote the effective management of T2DM.

show abstract

“…This poor adherence to prescribed regimen, then gets translated into worsening of conditions and increase in hospitalization and all-cause mortality to a significant extent. [11][12] Noncompliance and lack of persistence with treatment is the major problem associated with the therapy of coexistent hypertension and T2DM. Contributing reasons for this poor adherence may be polypharmacy, complex drug regimen, increased pill burden, cost and the need of long term therapy.…”

Section: Introductionmentioning

confidence: 99%

Formulation and Development of Fixed Dose Combination of Antihypertensive and Antidiabetic Agent for treatment of Co-existent Type Two Diabetes Mellitus and Hypertension

Ranpise¹,

Jamkar²,

Langote³

2014

IJPER

View full text Add to dashboard Cite

Objective: Coexistent Type Two Diabetes Mellitus (TTDM) and hypertension exposes patients to severe co-morbidities. Complex polypharmacy suggested by international organizations leads to the increased pill burden and decreased patient compliance which leads to worsening of conditions. Materials and Methods: Present research aims at the formulation and development of fixed dose combination (FDC) for treatment of coexistent hypertension and TTDM as it will help in increasing patient compliance. Literature survey and patient survey facilitated the selection of metformin HCl, telmisartan, atorvastatin and aspirin for the formulation of FDC. Formulation and development of enteric coated aspirin tablet and the bilayer tablet of metformin HCl, telmisartan & atorvastatin calcium were two major parts of this research.Aspirin was enteric coated by compression coating technique to avoid gastric irritation. Bilayer tablet separating metformin HCl layer from the layer of a mixture of telmisartan and atorvastatin calcium was prepared to avoid the physical incompatibility problem between metformin HCl and telmisartan.The final FDC formulation was prepared by encapsulating, enteric coated aspirin tablet and bilayer tablet in a size 00 capsule and subjected to accelerated stability studies. Results: Batch F2 of bilayer tablet containing one layer of metformin HCl and the other layer having a mixture of telmisartan& atorvastatin calcium releases more than 80% of metformin HCl, telmisartan and atorvastatin calcium within 1 hour. Batch A2E of enteric coated aspirin tablet was found to show delayed and complete drug release as compared to A2D within 3.5 hours. Similarity factor f2 was found to be 69.33. After long term storage of formulation at 40 o C/75% RH, stability of drug components remained unaffected. Conclusion: FDC of antihypertensive and antidiabetic agent will be revolutionary in the treatment of coexistent TTDM and hypertension as it will be a cheaper alternative to current therapy.

show abstract

Fixed-Dose Combination Antidiabetic Therapy: Real-World Factors Associated with Prescribing Choices and Relationship with Patient Satisfaction and Compliance

Cited by 53 publications

References 22 publications

Fixed Doses Combinations Acting on Cardiovascular System - Utilization and Generic Competition

Fixed Doses Combinations Acting on Cardiovascular System - Utilization and Generic Competition

Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals

Formulation and Development of Fixed Dose Combination of Antihypertensive and Antidiabetic Agent for treatment of Co-existent Type Two Diabetes Mellitus and Hypertension

Contact Info

Product

Resources

About